## Polygonum cuspidatum attenuates high-fat diet-induced NAFLD in rats: impact on untargeted serum metabolomics and liver lipidomics

ZHANG Huan<sup>a,b</sup>, SHAM Tungting<sup>a,b</sup>, LI Chang<sup>c</sup>, WANG Yi<sup>a</sup>, LI Chenyu<sup>a</sup>, CHENG King-yip Kenneth<sup>b,d</sup>, CHAN Shunwane<sup>\*</sup>, MOK Kam-wah Daniel<sup>a,b\*</sup>

## **Abstract:**

**Introduction:** The dried rhizome and root of Polygonum cuspidatum Sieb. et Zucc. (PCRR) has long been used to treat atherosclerosis, gastrointestinal disorders and liver disease. However, the underlying mechanism of PCRR against liver steatosis remains unclear.

Materials and Methods: A high-fat diet (HFD)-induced simple steatosis model in rats will be used to evaluate the therapeutic effect of polyphenol-rich water extract from PCRR. Its underlying mechanisms were revealed using untargeted mass spectrometry-based serum metabolomics, hepatic lipidomics profiling approaches and Western blotting assays.

Results: Our study showed that PCRR-treated rats displayed significant reduction of serum TC and LDL-C, hepatic TG, TC levels and total liver lipid contents under a high-fat diet feeding condition. Untargeted metabolomics showed that PCRR significantly restored overall levels of eight lipid classes in liver tissues and elevates the bile acids levels in the serum. We demonstrated that PCRR protected from steatosis by promoting hepatic triglyceride export and decreasing de novo lipogenesis via regulating AMPK/ACC/FAS/PPAR \alpha signaling pathway. Moreover, the antisteatotic effects of PCRR were related to increased cholesterol uptake and increased bile acids synthesis from cholesterol via regulating LDLR/CYP7A1 signaling pathway. Moreover, resveratrol and/or polydatinderived metabolites were solely detected in the serum of the PCRR-treated group,

<sup>&</sup>lt;sup>a</sup> Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong, China

<sup>&</sup>lt;sup>b</sup> Research Centre for Chinese Medicine Innovation (RCMI), The Hong Kong Polytechnic University, Hong Kong, China

<sup>&</sup>lt;sup>c</sup> School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China

<sup>&</sup>lt;sup>b</sup> Department of health technology and informatics, The Hong Kong Polytechnic University, Hong Kong, China

<sup>&</sup>lt;sup>c</sup> Department of Food and Health Sciences, Technological and Higher Education Institute of Hong Kong, Hong Kong, China

<sup>\*</sup>Correspondence: CHAN Shunwan; E-mail address: swchan@vtc.edu.hk

MOK Kamwah Daniel; E-mail address: daniel.mok@polyu.edu.hk

indicating these microbial transformed metabolites might partly contribute to the beneficial effects of PCRR.

**Conclusions:** Our findings suggest that PCRR could treat hepatic steatosis and its related dyslipidemia via multiple pathways.